Skip to main navigation Skip to search Skip to main content

Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial

  • Javed Butler
  • , Stephen E. Epstein
  • , Stephen J. Greene
  • , Arshed A. Quyyumi
  • , Sergey Sikora
  • , Raymond J. Kim
  • , Allen S. Anderson
  • , Jane E. Wilcox
  • , Nikolai I. Tankovich
  • , Michael J. Lipinski
  • , Yi An Ko
  • , Kenneth B. Margulies
  • , Robert T. Cole
  • , Hal A. Skopicki
  • , Mihai Gheorghiade
  • Stony Brook University
  • Washington Hospital Center
  • Duke University
  • Emory University
  • CardioCell LLC
  • Northwestern University
  • Stemedica Cell Technologies Inc
  • University of Pennsylvania

Research output: Contribution to journalArticlepeer-review

168 Scopus citations

Abstract

Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction ≤40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5×10 6 cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98-66.97; P=0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70-9.74; P=0.02) and functional status scores (+5.65, 95% confidence interval -0.11 to 11.41; P=0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalCirculation Research
Volume120
Issue number2
DOIs
StatePublished - Jan 20 2017

Keywords

  • cardiomyopathy
  • clinical trial
  • heart failure
  • noni
  • schemic
  • stem cells
  • viable myocardium

Fingerprint

Dive into the research topics of 'Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial'. Together they form a unique fingerprint.

Cite this